Stockreport

scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease

scPharmaceuticals Inc.  (SCPH) 
Last scpharmaceuticals inc. earnings: 3/24 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: scpharmaceuticals.com
PDF FDA approves scPharmaceuticals’ supplemental New Drug Application to expand the FUROSCIX indication to include the treatment of edema in adult patients with chronic kidn [Read more]